Market Overview

UPDATE: JMP Securities Initiates Coverage On Pacira Pharmaceuticals

Share:

In a note released Tuesday Morning, JMP analyst Oren Livnat initiated coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Market Perform rating, but has yet to set a price target.

The main focus of Livnat's note was the successful launch of Exparel, a non-opiod, post-surgical pain injection. He noted that Exparel is on the precipice of profitability in the second half of 2014. Moreover, he said all indications point to continued strong growth.

Livnat is optimistic on the future of Exparel and Pacira Pharmaceuticals and is predicting over $600 million and $5 EPS in 2017, but he believes this is adequately reflected in the stocks current price.

Livant concluded, "In our view, meaningful upside will require Exparel trajectory upside, pipeline advancement, or accretive M&A."

Following the release of the JMP note shares of Parcia Pharmaceuticals are trading up about two percent to ~$85.83.

Latest Ratings for PCRX

DateFirmActionFromTo
Feb 2019MizuhoDowngradesNeutralUnderperform
Nov 2018JP MorganMaintainsNeutralNeutral
Nov 2018BMO CapitalMaintainsMarket PerformMarket Perform

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: JMP Securities Oren LivnatAnalyst Color News Initiation Analyst Ratings

 

Related Articles (PCRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
YETIJefferiesMaintains40.0
DRIBank of AmericaReiterates130.0
PVACNorthland SecuritiesUpgrades0.0
NKEWells FargoMaintains80.0
DRIWells FargoMaintains120.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Top Performing Industries For June 17, 2014

UPDATE: UBS Initiates Coverage On Orbitz Emphasizing Loyalty Program, Growth Opportunities